High Levels of Serum Interleukin-10 Are Associated with a Poor Response to Interferon Treatment in Patients with Chronic Hepatitis C

References

• Di Bisceglie A M, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10
   PubMed Web of Science ®Google Scholar
• Davis G L, Balart L A, Schiff E R, Lindsay K, Bodenheimer H C, Perrillo R P. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501–6
   PubMed Web of Science ®Google Scholar
• García Buey L, López-Botet M, García-Sánchez A, Balboa M A, Arambaru J, García Monzón C. Variability in the expression of a β2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon. Hepatology 1993; 17: 372–82
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291–7
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M. Detection of hepatitis C virus by polymerase chain reaction and response to interferon α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–9
   PubMed Web of Science ®Google Scholar
• Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977–82
   PubMed Web of Science ®Google Scholar
• Lau J YN, Davis G L, Kniffen J, Qian K P, Urdea M S, Chan C S. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–83
   PubMed Web of Science ®Google Scholar
• Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121–30
   PubMed Web of Science ®Google Scholar
• Tsubota A, Chayama K, Ikeda K, Yasuji A, Kaida I, Saitoh S. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–94
   PubMed Web of Science ®Google Scholar
• Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995; 23: 487–96
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C. A comparison of three interferon alfa 2b regimens for the long-term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995; 332: 1457–62
   PubMed Web of Science ®Google Scholar
• Fiorentino D F, Bond M W, Mosmann TR. Two types of mouse helper T cell. IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081–95
   PubMed Web of Science ®Google Scholar
• Howard M, óGarra A. Biological properties of interleukin-10. Immunol Today 1992; 13: 198–200
   PubMedGoogle Scholar
• Gazzinelli R T, Oswald I P, James S L, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ activated macrophages. J Immunol 1992; 148: 1792–6
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, Te Velde A, Figdor C. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–24
   PubMed Web of Science ®Google Scholar
• Clerici M, Wynn T A, Berzofsky J A, Blatt S P, Hendrix C W, Sher A. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93: 768–75
   PubMed Web of Science ®Google Scholar
• Ghalib H W, Piuvezam M R, Skeiky Y AW, Siddig M, Hashim F A, El-Hassan A M. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 324–9
   PubMed Web of Science ®Google Scholar
• Sieling P A, Abrams J S, Yamamura M, Salgame P, Bloom B R, Rea T H. Immunosuppression roles for IL-10 and IL-4 in human infection. J Immunol 1993; 150: 5501–10
   PubMed Web of Science ®Google Scholar
• Kuzushita N, Hayashi N, Katayama K, Kanto T, Kawanishi Y, Mochizuki K. Elevated serum levels of IL-10 in patients with acute and chronic HCV infection [abstract]. Hepatology 1995; 22: 356A
   Web of Science ®Google Scholar
• Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425–34
   PubMed Web of Science ®Google Scholar
• Makgoba M W, Sanders M E, Ginther-Luce G E, Gugel E A, Dustin M L, Springer T A. Functional evidence that intercellular adhesion molecule-1 is a ligand for LFA-1 in cytotoxic T cell recognition. Eur J Immunol 1988; 18: 636–40
   Google Scholar
• Jander S, Heidenreich F, Stoll G. Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurological disease. Neurology 1993; 43: 1809–13
   PubMed Web of Science ®Google Scholar
• Mason J C, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 519–27
   PubMed Web of Science ®Google Scholar
• Adams D H, Mainnolfi E, Burra P, Neubcrgcr J M, Ayres R, Elias E. Detection of intercellular adhesion molecule-1 in chronic liver disease. Hepatology 1992; 16: 810–4
   PubMed Web of Science ®Google Scholar
• Seth R, Raymond R D, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991; 338: 83–4
   PubMed Web of Science ®Google Scholar
• Nouri-Aria K T, Koskinas J, Tibbs C J, Portmann B C, Williams R. Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to interferon α. Gut 1995; 36: 599–603
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kohara K, Yamaguchi K, Tanaka S, Hasegawa A, Ohta Y. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347–53
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Hiramatsu N, Ueda K, Takehara T. Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease. Gastroenterology 1992; 692–4
   PubMedGoogle Scholar
• Dexon W J, Brown M B, Engelman L, France J W, Hill M A, Jenrich R I. BMDP statistical software. University of California Press, Berkeley, CA 1985
   Google Scholar
• Haanen J BAG, De Waal Malefyt R, Res P CM, Kraakman E M, Ottenhoff T HM, De Vries R RP. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 1991; 174: 583–92
   PubMed Web of Science ®Google Scholar
• Barnes P F, Abrams J S, Lu S, Sieling P A, Rea T H, Modlin RL. Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun 1993; 61: 197–203
   PubMed Web of Science ®Google Scholar
• Moine O L, Marchant A, Durand F, Ickx B, Pradier O, Belighiti J. Systemic release of interleukin-10 during orthotopic liver transplantation. Hepatology 1994; 20: 889–92
   PubMed Web of Science ®Google Scholar
• Denis M, Ghadirian E. IL-10 neutralization augments mouse resistance to systemic mycobacterium avium infections. J Immunol 1993; 151: 5425–30
   PubMed Web of Science ®Google Scholar
• Chomarat P, Rissoan M C, Banchereau J, Miossec P. Interferon γ inhibits interleukin 10 production by monocytes. J Exp Med 1993; 177: 523–7
   PubMed Web of Science ®Google Scholar
• Nathan C F, Kaplan G, Levis W R, Nusrat A, Witmer M D, Shrwin S A. Local and systemic effects of intradermal recombinant interferon γ in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–15
   PubMed Web of Science ®Google Scholar
• Badaro R, Falcoff E, Badaro F S, Carvalho E M, Pedral-Sampaio D, Barral A. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322: 16–21
   PubMed Web of Science ®Google Scholar
• Holland A M, Eisenstein E M, Kuhns D B, Turner M L, Fleisher T A, Strober W. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348–55
   PubMed Web of Science ®Google Scholar
• Billardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. J Clin Invest 1995; 95: 2067–75
   PubMed Web of Science ®Google Scholar
• García Monzón C, García Buey L, García-Sánchez AS, Pajares J M, Moreno-Otero R. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. Gastroenterology 1993; 105: 462–9
   PubMed Web of Science ®Google Scholar